# AI MedSmarter — Combined Phase 9 + Phase 10 final report

**Branch:** `claude/amazing-darwin-kfj6sv` · **Date of work:** 2026-10-16 · **Scope:** Phase 9 (professional pharmacovigilance records) and Phase 10 (pharmacy safety and product concerns). **Phase 11 was not started.**

> **Not clinically validated. Not production-ready.** Everything here is internal record-keeping with synthetic data. No seriousness grade, causality score, regulatory schema or external report exists. MedSmarter is a **facilitator** of internal records; it is not a manufacturer, importer, national reporting authority or legally responsible reporting party. Persian wording is **awaiting clinical review** (no reviewer is named or invented).

## 0. Starting state — what the repository actually contained
The task text said Phase 9 "has not yet been implemented". The repository showed otherwise: commit `c3dc22b` already contained a **Phase 9** implementation (internal adverse-event record, conservative classification, human review, template assistance, web workspace, tests, `docs/phase9/`), built in an earlier session and pushed. I trusted the repository, **kept that work, and extended it** to meet the combined brief rather than rebuilding it. The Phase 10 module (`Pharmacies`) was an empty placeholder and was implemented from scratch.

## 1. Implementation summary

### Phase 9 (existing, verified, extended)
* **Existing, re-verified this session:** internal adverse-event record (stable id; reporter role and origin; suspected medicines linked to the patient's own record or kept as a name; event text, dates when known; outcome as stated; provenance; missing-information indicators; append-only history; "signal, not proof" and "internal record" notices; `NotSubmitted`); conservative classification (default **Unclassified**; only the five terms **defined in the WHO/FIP supplementary documents**; professional-only, reasoned, reversible, versioned); professional review (queue filtered per patient by relationship + consent, notes, information requests, free-text assessment, status moves, follow-ups, supplements that fill only unknowns); a **template** assistance with **no model** that is never stored; default-deny access; audit with ids only; web workspace for patient, physician, pharmacist.
* **Added this session (additive, migration `AddAdrDoseAndConcomitant`):** `doseAndAdministrationAsReported` (free text, immutable, never completed) and `concomitantMedications` (own record or name as given; **separate from suspected**; "not named" ≠ "none taken"), in the API, assistance, missing-information codes, web form and detail page.

### Phase 10 (new)
* **Dispensing-error / near-miss log** (`pharmacy.safety_event`): kinds `DispensingError` and `NearMiss` kept apart by *reached the patient* (yes/no/unknown, with refusing rules); optional example tags = the **eight examples of FIP §5.2.1** (quoted, cited, labelled "examples, not a complete or official list") plus MedSmarter's own "other"; optional date, medicine as named, how noticed/intercepted, immediate action; **no patient identifier**; unknown details stay unknown and are listed; review notes, follow-ups, status history; idempotent retries.
* **Product-concern intake** (`pharmacy.product_concern`): provisional types (`ProvisionalNotSourceDefined`); **linked** to a ProductTrace record only when the caller passes one they may read (identifiers copied as a snapshot with the record's version and verification) or **Unmatched** with the identifiers exactly as typed and what is missing flagged; both kept and a difference flagged when typed and linked values disagree; never chooses a batch, never declares a defect; optional verified links to an ADR record or a safety event.
* **Manufacturer-report boundary:** the existing mock pipeline is unchanged and not called; a reviewer can record a **human note** that a report "may be worth considering" (after review, once, with a reason) which creates, queues and sends **nothing**.
* **Web:** safety log and product-concern pages (list, form, detail, review block) for Pharmacist and PharmacyAdmin, en/fa, with the unreviewed-Persian banner.
* **Security model:** organization-scoped permissions `pharmacy.safety.create/read/review` (Pharmacist, PharmacyAdmin only); the owning organization is read from the record; uniform 403.

## 2. Status of features
| Item | Status |
|---|---|
| ADR internal record, classification, review, assistance (Phase 9) | **Implemented** (pre-existing, re-verified) |
| ADR dose/administration and concomitant medicines | **Implemented** (this session) |
| Dispensing-error and near-miss log | **Implemented** |
| Product-concern intake linked to ProductTrace / unmatched | **Implemented** |
| Manufacturer-report human note | **Implemented** (note only) |
| Cross-links ADR ↔ concern ↔ safety event | **Implemented** (verified at creation; stored as ids) |
| Web UI for all of the above | **Implemented** |
| Flutter screens for ADR and pharmacy safety | **Not implemented** (deferred; Flutter only received regenerated catalog/strings) |
| Product-record picker (patient/batch lookup) in the pharmacy UI | **Partially** — ids are typed; unmatched works without |
| AI assistance beyond the fixed template (real model) | **Deferred / blocked** (no validation; gated provider decision) |
| Pharmacy-initiated manufacturer report, any adapter, E2B/MedDRA, analytics, seriousness/causality | **Deferred / blocked** (sources, legal basis, approvals missing) |
| Emergency/urgent escalation | **Blocked** (not designed; pages say they send no urgent alerts) |

## 3. Source files actually inspected and limits of interpretation
* **Lecture slides (only three unique files):** Shalviri (industry), Karimi Ghovanlou (patients; **uploaded twice, byte-identical**), Mohebbi (AI). **Not re-read in this session**; their content comes from the earlier source analysis (`docs/pharmacovigilance-source-analysis.md`). Limits unchanged: Shalviri slide 6 (Iranian manufacturer/importer instruction) is a **screenshot whose exact wording is unverified**; Karimi Ghovanlou slide 18 gives **titles only** of the methotrexate and NSAID cases.
* **Supplementary, not slides:** WHO 2025 strategy, FIP 2020 report, npj scoping review, the Persian Excel comparison (**authorship unverified; kept, not used as evidence**). The WHO and FIP documents were read **selectively, not page by page**. This session I **re-read the FIP extracted text** for §5.2.1 (the eight examples and the "For example:" introduction) and §1.1 (near miss); the PDFs are in the session uploads, **not in the repository**.
* **Interpretation limits:** the FIP list is explicitly illustrative; page numbers in the extracted text were inconsistent, so citations say "to be re-checked against the original"; the sources define neither "product-quality defect" nor "lack of effect", and establish no national form, seriousness criteria, causality method, deadlines or Iranian reporting pathway. None of this is claimed anywhere.
* **Repository inspected:** ADR placeholder → Phase 9 code, Pharmacies/Pharmacists modules (placeholders), Patients, ProductTrace (contracts, manufacturer-report pipeline), Guidance, ClinicalRules, AI, Consent, Identity/authorizer, Audit, the access catalog, Phase 0 roadmap and decisions, Phase 3–9 docs.

## 4. Product-wide traceability
`docs/pharmacovigilance-traceability-matrix.md` updated: rows P-05…P-08, I-07…I-09, N-02 revised; new rows D-def-3, D-def-4, I-16…I-20, Q-12, Q-13. All four evidence levels stay distinct (slide / supplementary / design / open) and each row names module, phase status, tests and approvals still needed. The source analysis, `docs/phase9/` (new `11-extension-dose-and-concomitant.md`) and `docs/phase10/` (new, six documents) are cross-linked.

## 5. Changed files and architecture
**New:** `Modules/Pharmacies.Contracts/PharmacySafetyContracts.cs`; `Modules/Pharmacies/{PharmacySafetyService.cs, Persistence/PharmacyDbContext.cs, Persistence/Migrations/*InitialPharmacySafetySchema*}`; `Host/Pharmacy/PharmacySafetyEndpoints.cs`; `Modules/ADR/.../Migrations/*AddAdrDoseAndConcomitant*`; web `pharmacy/{api,types}.ts`, `features/pharmacysafety/*`, `scripts/phase10-qa.mjs`, `__tests__/phase10.test.tsx`; tests `Phase10Tests.cs`, `Phase10ApiTests.cs`; docs `docs/phase10/*`, `docs/phase9/11-*`, `docs/phase9-10/*`.
**Modified:** ADR contracts/service/DbContext/endpoints types and web form/detail (dose, concomitant); `PharmaciesModule`, its csproj; `AuditContracts.cs` (+6 constants); `security/access-catalog.json` (+3 permissions) and generated files (C#, TS, Dart, JSON); `Program.cs` (one line); `routes.tsx`, `layouts/roles.ts`; `design/i18n/strings.mjs` + generated JSON; `Fixture.cs` (register modules); `Phase9Tests.cs`, `phase9.test.tsx`; docs (`phase0/10-roadmap.md` pointer note, `phase9/README`, `03`, `08`, traceability matrix).
**Data model:** schema `adr` (+2 columns), new schema `pharmacy` (3 tables). **API:** +12 routes (Phase 10). **No** Docker, CI, hosting or external service was added.

## 6. Security, authorization, consent, privacy, audit
* Default deny; catalog permission → organization membership of the **owning** organization (record-derived); identical 403 for "missing" and "someone else's".
* Cross-organization: a pharmacist cannot create in, list, read or review another organization's records (tested over HTTP, including a record created in the other organization).
* Links: an **ADR link** needs that record's own relationship + consent; a **ProductTrace link** needs that patient's relationship + `products` consent at link time, else refused (never substituted). Patient ids are never returned by pharmacy responses.
* Separation of voices (ADR): patient report / professional entries / template assistance / professional conclusions are distinct; patients never see professional notes, assessments, category or author ids.
* Audit: ids, enum names, org id only; a test proves distinctive report text appears nowhere in audit.
* No outbound path in either module (assembly-reference tests); the manufacturer-report outbox is unchanged by Phase 10 (tested); no insurer access.
* Free text is stored as typed; **screening is not anonymization and none is claimed**.

## 7. Exact commands and results
Environment: local only. PostgreSQL 16 (already installed locally; its stopped cluster was restarted with `pg_ctlcluster 16 main start`); scratch databases; `dotnet`, `node`, `flutter` already installed.

| Command | Result |
|---|---|
| `dotnet build --no-incremental` (warnings as errors) | **0 warnings, 0 errors** |
| `dotnet test tests/MedSmarter.ArchitectureTests` | 6 passed |
| `… BuildingBlocks.Tests` | 4 passed |
| `… Api.Tests` | 8 passed |
| `… Knowledge.Tests` (in memory) | 290 passed, **15 skipped** (PostgreSQL-only) |
| `… Patients.Tests` (in memory) | **436 passed, 7 skipped** (PostgreSQL-only), total 443 — includes Phase 4–8 regressions, the Phase 5 manufacturer-report consent/minimization tests, **32 new tests this session** (1 ADR extension + 31 Phase 10) |
| `… Security.Tests` | 133 passed |
| `… IntegrationTests` | **3 skipped — not run** (need the Docker compose stack, not provisioned) |
| `MEDSMARTER_PG_TEST=… dotnet test tests/MedSmarter.Patients.Tests` | **443 passed, 0 skipped** |
| `MEDSMARTER_PG_TEST=<fresh migrated DB> dotnet test tests/MedSmarter.Knowledge.Tests` | **305 passed, 0 skipped** |
| `dotnet ef migrations has-pending-model-changes` × 9 contexts (Adr, Audit, ClinicalRules, Consent, Guidance, Medications, Patients, **Pharmacy**, ProductTrace) | "No changes" for all 9 |
| `--migrate-and-exit` on an empty PostgreSQL DB | 9 migrators applied; `adr.adverse_event(_entry)`, `pharmacy.safety_event`, `pharmacy.product_concern`, `pharmacy.safety_entry` present |
| `node design/build.mjs --check`, `node security/build.mjs --check` | up to date |
| `eslint src scripts`, `tsc -b` | clean |
| `vitest run` | **297 tests, 15 files, all passed** |
| `vite build` | OK |
| `node web/scripts/phase9-qa.mjs` (Chromium + axe; en/fa × light/dark × desktop/phone; real API on PostgreSQL) | **178 checks, 0 failures** |
| `node web/scripts/phase10-qa.mjs` (same matrix × pharmacist and pharmacy administrator) | **270 checks, 0 failures** |
| `flutter analyze`; `flutter test` | analyze clean; **157 tests passed** |
Both browser runs passed on their final execution; the Phase 9 QA of the previous session had found one real overflow defect (already fixed then). Environment note: the local PostgreSQL cluster had stopped and was restarted before the database runs.

## 8. Tests skipped or not run, with reasons
* `IntegrationTests` (3): require the Docker compose stack; not provisioned (not authorized).
* In-memory runs skip 15 (Knowledge) + 7 (Patients) PostgreSQL-only tests; those **were run** separately against local PostgreSQL (305/305 and 443/443). Nothing skipped is claimed as passed.
* **Flutter build** (`flutter build …`) was not run: no Flutter source changed except generated catalog/strings, and no new platform tooling was set up.
* No load, multi-instance, penetration or accessibility test beyond axe on the checked pages was run; no manual screen-reader test.

## 9. Known defects and limitations
No known failing test. Limitations: no Flutter screens; pharmacy product-record link by typed ids (no picker); first organization only in the UI; no independent-reviewer rule for pharmacy records; the audit line is written after the data commit (the Phase 5 trade-off); date inputs carry a date only; the queue (ADR) checks consent per patient on each call (fine for the demo, to optimise before scale); FIP page numbers to be re-checked; assistance is a template (no model); no retention policy, DPIA or emergency path.

## 10. Reviews still needed
* **Clinical:** ADR field set and category list; the near-miss/error pairing rule; example-tag wording; provisional concern types; status sets.
* **Regulatory/legal:** any reporting by a pharmacy or on a patient's behalf; the unverified Shalviri slide-6 instruction (obligations of manufacturers/importers are **not** MedSmarter's); legal basis and agreements for any transmission; retention of linked snapshots after consent revocation.
* **Privacy:** DPIA, retention, access review for a pilot; free text may contain anything typed.
* **Persian:** all Persian wording (`adr.*`, `ph.*`, error texts) awaits a **named qualified reviewer**; no Persian definitions of near miss/ADR exist; no reviewer registry exists, so "Approved" is unreachable.
* **Sources:** verify the Excel's provenance; re-check FIP page numbers; obtain slide-18 case content; read the WHO/FIP documents exhaustively if any further requirement is to rely on them.

## 11. Roadmap changes and next recommended phase
`docs/phase0/10-roadmap.md` (Phase 0 plan numbering) was **not renumbered**; only a pointer note was added (and extended to say delivered Phase 10 has no Phase 0 equivalent); `docs/phase9/08-roadmap-reconciliation.md` maps planned to delivered phases. Historical reports are unchanged except small "update" pointers in the Phase 9 README.
**Recommended next phase (not started):** first resolve the decisions below, then either (a) **Flutter parity + patient/batch picker + reviewer registry for Persian wording** (low risk, no new authority needed), or (b) the **reporting-pathway design** (blocked until an authoritative Iranian specification and legal basis exist). Do not start any real transmission, manufacturer/regulator adapter, seriousness/causality scoring or real AI assistance without those approvals.
**Decisions needed from you:** pharmacy's role in reporting; authoritative national documents; a clinical reviewer and a Persian wording reviewer; whether to require an independent reviewer for pharmacy records; retention periods; whether Flutter parity precedes further web features; verify or discard the Excel comparison.

## 12. Explicit confirmation
**No paid resource, real external integration, real report transmission or outbound network call was used.** All tests and the browser QA ran against local, synthetic demonstration data; PostgreSQL was a local scratch instance (databases dropped afterwards); the manufacturer-report provider remained `Mock`; no AI provider was configured or called; no web request was made to fill source gaps; nothing in either module can send a record anywhere.
